Significance of one human leukocyte antigen mismatch on outcome of nonmyeloablative allogeneic stem cell transplantation from related donors using the Mexican schedule

Bone Marrow Transplantation

Volumn 35, Issue 4, 2005, Pages 335-339

  Ruiz Arguelles G J ^a,b   Lopez Martinez B ^b   Manzano, C ^c   Gomez Rangel J D ^d   Lobato Mendizabal E ^a  

^a Ctro Hematol Med Int de Puebla   (Mexico)

^b Laboratorios Clinicos de Puebla   (Mexico)

^c BENEMÉRITA UNIVERSIDAD AUTÓNOMA DE PUEBLA   (Mexico)

^d UNIVERSIDAD POPULAR AUTÓNOMA DEL ESTADO DE PUEBLA   (Mexico)

Author keywords

Allograft; Bone marrow; HLA; Matched; Mismatched; Nonablative; Outcome; Sibling

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; BUSULFAN; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; ITRACONAZOLE; LEUKOCYTE ANTIGEN; METHOTREXATE; ONDANSETRON;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ALLOGRAFT; APLASTIC ANEMIA; ARTICLE; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DONOR; FEMALE; GRAFT SURVIVAL; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HLA MATCHING; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; OUTCOMES RESEARCH; PREVALENCE; PRIORITY JOURNAL; PROLYMPHOCYTIC LEUKEMIA; SIBLING; TECHNIQUE;

BLOOD DONORS; FEMALE; HEMATOLOGIC NEOPLASMS; HISTOCOMPATIBILITY TESTING; HUMANS; MALE; MEXICO; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; SIBLINGS; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 14644427235     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704780     Document Type: Article

References (37)

1. Butturini A, Gale RP. Allogeneic bone marrow transplantation for leukemia. Curr Opin Hematol 1994; 1: 402-405.
2. Tsimberidou AM, Stavroyianni N, Viniou N, The Hellenic Cooperative Group et al. Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia. Cancer 2003; 97: 1721-1731.
3. Georges G, Storb R. Review of 'minitransplantation': nonmyeloablative allogeneic hematopoietic stem cell transplantation. Int J Hematol 2003; 77: 3-14.
4. Djulbegovic B, Seidenfeld J, Bonnell C, Kumar A. Nonmyeloablative allogeneic stem-cell transplantation for hematologic malignancies: a systematic review. Cancer Control 2003; 10: 17-31.
5. Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematological diseases. Blood 1998; 91: 756-763.
6. Giralt S, Estey E, Albitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeoablative therapy. Blood 1997; 89: 4531-4536.
7. Ruiz-Argüelles GJ, Gómez-Almaguer D, Ruiz-Argüelles A et al. Results of an outpatient-based stem cell allotransplant program using non-myeloablative conditioning regimens. Am J Hematol 2001; 66: 241-244.
8. Gómez-Almaguer D, Ruiz-Argüelles GJ, Ruiz-Argüelles A et al. Hematopoietic stem cell allografts using a nonmyeloablative conditioning regimen can be safely performed on an outpatient basis. Bone Marrow Transplant 2000; 25: 131-133.
9. Ruiz-Argüelles GJ. Allogeneic stem cell transplantation using non-myeloablative conditioning regimens: results of the Mexican approach. Int J Hematol 2002; 76U (Suppl 1): 376-379.
10. Ruiz-Argüelles GJ. Non-myeloablative bone marrow transplantation. Arch Med Res 2003; 34: 554-557.
11. Gómez-Almaguer D. The simplification of the SCT procedures in developing countries has resulted in cost-lowering and availability to more patients. Int J Hematol 2002; 76 (Suppl 1): 380-382.
12. Barr RD. The importance of lowering the costs of stem cell transplantation in developing countries. Int J Hematol 2002; 76 U (Suppl 1): 365-367.
13. Ruiz-Argüelles GJ, López-Martínez B, Gómez-Rangel D et al. Decreased transfusion requirements in patients given stem cell allografts using a non-myeloablative conditioning regimen: a single institution experience. Hematology 2003; 8: 151-154.
14. Ruiz-Argüelles GJ, Gómez-Rangel JD, Ponce-de-León S et al. The Mexican schedule to conduct allogeneic stem cell transplantation is related to a low risk of cytomegalovirus reactivation and disease. Am J Hematol 2004; 75: 200-204.
15. Ruiz-Argüelles GJ, Gómez-Almaguer D, López-Martínez B et al. No cytomegalovirus-related deaths after non-ablative stem cell allografts. Hematology 2002; 7: 95-99.
16. Ruiz-Argüelles GJ, Gómez-Almaguer D, López-Martínez B et al. Results of an allogeneic non-myeloablative stem cell transplantation program in patients with chronic myelogenous leukemia. Haematologica 2002; 87: 894-896.
17. Ruiz-Argüelles GJ, Gómez-Almaguer D, Gómez Rancel JD et al. Allogeneic hematopoietic stem cell transplantation with non-myeloablative conditioning in patients with acute leukemia eligible for conventional allografting: a prospective study. Leukemia Lymphoma 2004; 45: 1191-1195.
18. Kessinger A, Armitage JO, Landmark JD et al. Autologous peripheral hematopoietic stem cell transplantation restores hemopoietic function following marrow ablative therapy. Blood 1998; 71: 723-727.
19. Ruiz-Argüelles A. Flow cytometry in the clinical laboratory. Principles, applications and problems. Ann Biol Clin 1992; 50: 735-743.
20. Ruiz-Argüelles A, Orfao A. Caracterización y evaluación de células totipotenciales en sangre periférica y médula ósea. In: Ruiz-Argüelles GJ, San-Miguel JF (eds). Actualización en Leucemias. Editorial Médica Panamericana: México City, 1996 pp 79-82.
21. Pinkel D, Straume T, Gray JW. Cytogenetic analysis using quantitative, high sensitivity fluorescence hybridization. Proc Natl Acad Sci USA 1996; 83: 2934-2938.
22. Ruiz-Argüelles GJ, López-Martínez B, Santellán-Olea MR et al. Follow up of hemopoietic chimerism in individuals given allogeneic hemopoietic stem cell allografts using an immunosuppressive, non-myeloablative conditioning regimen: a prospective study in a single institution. Leukemia Lymphoma 2002; 43: 1509-1511.
23. Yam P, Petz L, Knowlton R et al. Use of DNA restriction fragment length polymorphisms to document marrow engraftment and mixed hematopoietic chimerism following bone marrow transplantation. Transplantation 1987; 43: 399-407.
24. Ruiz-Argüelles GJ, Garcés-Eisele J, Reyes-Núñez V et al. Assessment of residual disease in acute leukemia by means of polymerase chain reaction: a prospective study in a single institution. Rev Invest Clin Mex 2000; 52: 118-124.
25. Champlin R. Nonmyeloablative chemotherapy with allogeneic hematopoietic transplantation as adoptive immunotherapy for malignancies. In: Schechter GP, Hoffman R, Schrier SL (eds). Hematology. The American Society of Hematology Education Program Book: Washington, USA, 1999, pp 413-416.
26. Or R, Shapira MY, Resnick I et al. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 2003; 101: 441-445.
27. Martino R, Caballero MD, Simon JA et al. Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood 2002; 100: 2243-2245.
28. Burnett AK, Wheatley K, Goldstone AH et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol 2002; 118: 385-400.
29. Greinix HT, Nachbaur D, Krieger O et al. Factors affecting long-term outcome after allogeneic haematopoietic stem cell transplantation for acute myelogenous leukaemia: a retrospective study of 172 adult patients reported to the Austrian Stem Cell Transplantation Registry. Br J Haematol 2002; 117: 914-923.
30. Feinstein Lyle C, Sandmaier BM, Hegenbart U et al. Non-myeloablative allografting from human leukocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission. Br J Haematol 2003; 1209: 281-288.
31. Sayer HG, Kroger M, Beyer J et al. Reduced intensity conditioning for allogeneic hematopoietic stem cell trasplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplant 2003; 12 1089-1095.
32. Anasetti C, Beatty PG, Stirb R et al. Effect of HLA incompatibility on graft versus host disease, relapse and survival after marrow transplantation in patients with leukemia and lymphoma. Hum Immunol 1990; 29: 79-91.
33. Ottinger H, Beelen D, Sayer H et al. Bone marrow transplantation from partially HLA matched related donors in adults with leukemia: The experience at the University Hospital of Essen, Germany. Br J Haematol 1996; 92: 913-921.
34. Bacigalupo A, Hows J, Gordon-Smith EC et al. Bone marrow transplantation for severe apalstic anemia from donors other tha HLA identical siblings: a report from the BMT Working Party. Bone Marrow Transplant 1988; 3: 531-535.
35. Powles RL, Morgenterns GR, Kay HE et al. Mismatched family donors for bone marrow transplantation as treatment for acute leukemia. Lancet 1983; 1: 612-625.
36. Hasegawa W, Lipton JH, Messner HA et al. Influence of one human leukocyte antigen mismatch on outcome of allogeneic bone marrow transplantation from related donors. Hematology 2003; 8: 27-33.
37. Ruiz-Argüelles GJ, Gómez-Almaguer D. Braking dogmata to help patients: non-myeloablative hematopoietic stem cell transplantation. Expert Opin Biol Ther 2004; 4: 1693-1699.